An overview of endothelial dysfunction in diabetes

Haiju H Chirayath*
Consultant Endocrinologist, Medcare Hospital, Dubai, United Arab Emirates

The endothelium is a single layer of cells constituting the innermost surface of the wall of a vessel. It forms the interface between blood flow and the blood vessel wall. Previously thought to be an inert layer of cells, it is now known to regulate vasomotor tone, by secreting various vasoactive factors which modulate both relaxation and constriction. The endothelium also maintains the anticoagulant, antplatelet, and fibrinolytic properties of vascular cells. In response to physical and chemical signals, the healthy endothelium produces a wide range of factors that regulate vasotone, cellular adhesion, thromboreistance, smooth muscle cell proliferation, and vessel wall inflammation [1]. The interest in endothelial function is based on its pivotal role in various diseases such as diabetes, coronary artery disease, cerebro-vascular disease and hypertension. Research into endothelial function may pave the way for novel therapies aimed at alleviating the morbidity and mortality from these conditions. Furthermore, as endothelial dysfunction is a common underlying feature of these interrelated disorders, it may be possible to apply knowledge gained by studying one disease to another disease process.

The endothelium secretes a number of mediators involved in vasodilation, the main ones being nitric oxide (NO), prostacycin (PGI2) and the endothelium derived hyperpolarizing factor (EDHF). NO is a crucial vasodilator which exerts an anti-aggregatory effect and also limits vascular smooth muscle cell growth and migration. Under certain conditions, the endothelium also produces endothelium-derived vasoconstrictors such as endothelin, prostaglandin H2 and thromboxane A2, which activate specific receptors on the vascular smooth muscle [2].

Mechanisms of hyperglycemia-induced endothelial dysfunction

Key processes responsible for hyperglycemia-induced endothelial dysfunction include the polyol pathway, reactive oxygen species (ROS) production, and advanced glycation endproducts (AGEs) formation [3]. One of the reasons endothelial cells are more susceptible to the effects of hyperglycaemia is because of their high expression of the insulin-independent protein that facilitates glucose transport(glucose transporter type 1 or GLUT-1), and the fact that they cannot regulate the glucose uptake through insulin action. This probably makes the endothelial cell more vulnerable to the deleterious effects of hyperglycemia than the smooth muscle cells, which can down-regulate GLUT-1 in response to increasing glucose concentrations [4].

The excess glucose in endothelial cells enters the polyol pathway causing the accumulation of the electron donors like reduced Nicotinamide Adenine Dinucleotide (NADH) and Flavin Adenine Dinucleotide (FADH2) in the mitochondria. This affects the electron transport chain with the excess electrons increasing ROS in mitochondria. ROS in turn trigger accumulation of AGEs and this process results in mitochondrial DNA damage and mitochondrial dysfunction[5]. Protein kinase C (PKC) and AGE mediated activation of nuclear factor kappa B (NFκB) lead to the expression of inflammation proteins, tumor suppressor p53, and inducible nitric oxide synthase (iNOS). The latter enzyme leads to increased NO production. NO is highly reactive with superoxide anions and the peroxynitrite generated acts as a strong oxidant. A vicious cycle is thereby set in motion where increasing ROS production increases oxidative stress [6]. In addition to the injury mechanisms, the impairment of protective factors in diabetes also plays a role in endothelial dysfunction. These include resistance to insulin, decrease of endogenous antioxidant enzymes, and dysfunction of endothelial progenitor cells [3]. Endothelial progenitor cells (EPCs) are circulating cells thought to originate from bone marrow, that follow chemokine signaling to reach sites that require neovascularization and vascular repair [7]. EPC number and function have been shown to be significantly diminished in diabetic patients, with reduced levels of up to 50% in diabetic patients compared to healthy controls [8]. Furthermore, EPCs were found to negatively correlate with disease severity [9].

Hyperglycemia-induced oxidative stress in endothelial cells has also been reported to upregulate plasminogen activator inhibitor 1 (PAI1), which prevents fibrinolysis [10] in addition to down regulating the platelet inhibitor prostacycin [11]. These events collectively increase the adhesion of macrophages and platelets to the endothelium, which in turn increase the risk for ischemic heart disease and cerebro-vascular disease in addition to other vascular diseases in diabetes. Current knowledge suggests that endothelial injury and dysfunction occur as the initial event in the pathogenesis of atherosclerosis, followed by platelet adhesion and aggregation [12].

Impaired endothelium-dependent vasodilation has been demonstrated in various vascular beds such as forearm, cerebral, coronary and subcutaneous arteries in patients with diabetes as well as various animal models of this disease. Impaired endothelial cell self-renewal with reduced turnover potential has been noted in the retinal microvasculature of diabetic rats [13]. This leads to hypoxia, which upregulates vascular endothelial growth factor (VEGF), contributing to elevated vascular permeability [14]. This can result in diabetic macular edema progressing to possible loss of visual function [15].

The discovery of endothelial microparticles (EMP)s revealed another factor contributing to endothelial dysfunction. EMPs are...

**Correspondence to:** Haiju H Chirayath, PhD, MSc, MRCP(UK), Consultant Endocrinologist, Medcare Hospital, Dubai, United Arab Emirates, E-mail: haiju.chirayath@gmail.com

**Key words:** diabetes, endothelial dysfunction, endothelium

**Received:** November 05, 2016; **Accepted:** November 21, 2016; **Published:** November 24, 2016
membrane vesicles derived from activated or apoptotic endothelial cells. The plasma level of EMPs is significantly elevated in diabetic patients compared to age-matched healthy controls [16], with levels being higher in diabetic patients with vascular complications [17]. Studies have demonstrated that EMPs contribute to coagulation [18], disruption of angiogenesis [19], and cerebral capillary damage [20], in addition to other vascular effects such as inflammation [21]. These EMPs may have pathogenic effects in vascular thrombosis and angiogenesis [22], which are essential for the development of DM and its complications.

Endothelial dysfunction is closely associated with insulin resistance, which is a common feature of diabetes, obesity, hypertension, and coronary artery disease. It refers to the state of decreased insulin response [23] and is associated with glucotoxicity, lipotoxicity, and inflammation, which initiates and accelerates atherogenesis and vascular disease [24]. The molecular mechanisms of insulin resistance have been delineated and impairment of the PI3-K/Akt signalling pathway has been noted, which leads to an inadequate tissue insulin sensitivity. This in turn leads to compensatory hyperinsulinemia, which contributes to diminished activity of the PI3-K/Akt pathway and enhancement of the MAPK/ERK pathway [25]. The differences in activity of both pathways lead to various effects of insulin resistance in different organs, such as the lack of suppression of glucose production by insulin and maintained lipogenesis in the liver [26] or decreased production of nitric oxide and enhanced production of ET-1 in endothelium [27].

Improving endothelial function in diabetes

The management of diabetes previously revolved around normalizing blood glucose levels, but as we learn more and more about this disease, the importance of maintaining optimum endothelial function is becoming clearer. Indeed, it is possible that future management of diabetes may include therapies focusing purely on improving endothelial function rather than solely lowering blood glucose levels. This paradigm shift may help in reducing the various vascular complications of diabetes including ischemic heart disease and cerebro-vascular disease.

The options for improving endothelial function in diabetes involve both lifestyle factors and medications. Some of the lifestyle modifications known to improve diabetes control such as reducing food intake and exercise have also been demonstrated to enhance endothelial function. Decreasing caloric intake has been shown to trigger endothelial AMPK-PI3K-Akt-eNOS activation leading to normalization of endothelial function and systolic BP reduction in Zucker obese rats [28]. Caloric restriction also improved vascular compliance [29] and revascularization in response to ischemia [30].

The type of food consumed has been shown to affect endothelial function. A diet high in polyunsaturated fatty acids (Mediterranean diet) was shown to increase EPC and reduce oxidative stress [31,32]. Exercise has been demonstrated to increase the number of EPC and improve their migratory capacity, thereby helping to repair damaged endothelium [32,33].

Various medications that are currently in use for managing diabetes have also been shown to improve endothelial function. The first-line drug in the management of Type 2 diabetes is Metformin and this drug is believed to enhance endothelial function through AMP-activated protein kinase (AMPK), which leads to phosphorylation of eNOS, thereby stimulating the release of the endothelium-derived vasodilator NO [34]. The key drug insulin exerts its pharmacological effect on the endothelium by activating the insulin receptor on endothelial cells, which leads to PI3K/PKB-dependent phosphorylation of eNOS and stimulation of NO production [35]. The glucagon-like peptide -1 (GLP-1) receptor agonist Exenatid-4 (from which Exenatide is derived), has been shown to increase NO production, stimulate proliferation and protect from lipid-induced apoptosis of human coronary artery endothelial cells, through PI3K/protein kinase B, protein kinase A and eNOS-dependent pathways [36]. Other existing drugs used in diabetes management that have effects on endothelial function include statins, phosphodiesterase-5 inhibitors, calcium channel blockers, beta blockers and ACE inhibitors [37].

In the future, EPCs may potentially be used for therapeutic purposes to aid regeneration of ischemic tissues; due to their ability to migrate to remote areas and promote new blood vessel formation in regions with vascular insufficiency [38]. Various strategies are being investigated to reverse EPC dysfunction caused by diabetes including enhancement of angiogenic stimulus using G-CSF (granulocyte-macrophage colony-stimulating factor) [39] and usage of nitric oxide donor to reverse stromal cell-derived factor 1 (SDF-1) mediated migration defects [40]. These strategies may potentially lead to novel treatments which normalize impaired endothelial function by regenerating damaged endothelial cells. Other new treatment options for improving endothelial function are also being researched currently. These include the eNOS transcription enhancer AVE3085, Ibrabradine and Sphingosine-1-phosphate amongst others [41-43].

In summary, endothelial dysfunction associated with diabetes is one of the important causes for the morbidity and mortality associated with this disease. Understanding the pathogenesis and molecular pathways of endothelial will help formulate novel therapeutic options in the future. With the dramatically rising prevalence of diabetes worldwide, it is hoped that this knowledge will help minimize the complications of diabetes and attenuate its future impact on global health.

References

Chirayath HH (2016) An overview of endothelial dysfunction in diabetes


33. Volakls KA, Tokmakidis SP, Halle M (2013) Acute and chronic effects of exercise on circulating endothelial progenitor cells in healthy and diseased patients. *Clin Res Cardiol* 102: 249-257. [Crossref]


